SMITH PATRICK F

SEC source: 0001415889-24-024874 · form4-10082024_081013.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,091

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2024.

SEC source: 0001415889-24-024816 · form4-10072024_081059.xml · derivative · entry 3

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,303

Underlying: Common Stock · 7,151 shares

Expires 2026-10-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on October 5, 2023, under the Certara, Inc. ("Certara") 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on October 4, 2024. The remaining two-thirds of the RSUs are scheduled to vest and settle in equal parts on October 5, 2025, and October 5, 2026.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on October 5, 2023, under the Certara, Inc. ("Certara") 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on October 4, 2024. The remaining two-thirds of the RSUs are scheduled to vest and settle in equal parts on October 5, 2025, and October 5, 2026.

SEC source: 0001415889-24-024816 · form4-10072024_081059.xml · nonDerivative · entry 2

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,500

F2 · shares: Represents RSUs of Certara withheld to satisfy tax withholding obligations in connection with the vesting of RSUs described in footnote 1, exempt under Rule 16b-3.

SEC source: 0001415889-24-024816 · form4-10072024_081059.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,242

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") was granted on October 5, 2023, under the Certara, Inc. ("Certara") 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on October 4, 2024. The remaining two-thirds of the RSUs are scheduled to vest and settle in equal parts on October 5, 2025, and October 5, 2026.

SEC source: 0001415889-24-010291 · form4-04042024_080424.xml · nonDerivative · entry 6

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,091

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2023.

F7 · price: This transaction was executed in multiple trades at prices ranging from $17.70 to $17.85. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-010291 · form4-04042024_080424.xml · nonDerivative · entry 5

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,513

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2023.

F6 · price: This transaction was executed in multiple trades at prices ranging from $16.50 to $17.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-010291 · form4-04042024_080424.xml · nonDerivative · entry 4

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,253

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2023.

F5 · price: This transaction was executed in multiple trades at prices ranging from $17.53 to $17.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-010291 · form4-04042024_080424.xml · nonDerivative · entry 3

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,581

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2023.

F4 · price: This transaction was executed in multiple trades at prices ranging from $16.49 to $16.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-010291 · form4-04042024_080424.xml · nonDerivative · entry 2

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,605

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $17.53 to $17.85. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-010291 · form4-04042024_080424.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,254

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $16.50 to $16.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-010073 · form4-04032024_090432.xml · derivative · entry 8

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,381

Underlying: Common Stock · 30,381 shares

Expires 2027-04-01

F6 · derivative.exercise_price: Each RSU was granted on April 1, 2024, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. The RSUs will vest and settle in three equal installments on April 1, 2025, April 1, 2026 and April 1, 2027.

F6 · derivative.exercise_date: Each RSU was granted on April 1, 2024, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. The RSUs will vest and settle in three equal installments on April 1, 2025, April 1, 2026 and April 1, 2027.

SEC source: 0001415889-24-010073 · form4-04032024_090432.xml · derivative · entry 7

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,704

Underlying: Common Stock · 7,852 shares

Expires 2026-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU was granted on April 1, 2023, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on April 1, 2024. The remaining two-thirds of the RSUs are scheduled to vest and settle in equal parts on April 1, 2025 and April 1, 2026.

F5 · derivative.exercise_date: Each RSU was granted on April 1, 2023, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on April 1, 2024. The remaining two-thirds of the RSUs are scheduled to vest and settle in equal parts on April 1, 2025 and April 1, 2026.

SEC source: 0001415889-24-010073 · form4-04032024_090432.xml · derivative · entry 6

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,647

Underlying: Common Stock · 8,646 shares

Expires 2025-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU was granted on April 1, 2022, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on March 31, 2023. One-third of the RSUs vested and were settled on April 1, 2024. The remaining one-third of the RSUs are scheduled to vest and settle on April 1, 2025.

F4 · derivative.exercise_date: Each RSU was granted on April 1, 2022, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on March 31, 2023. One-third of the RSUs vested and were settled on April 1, 2024. The remaining one-third of the RSUs are scheduled to vest and settle on April 1, 2025.

SEC source: 0001415889-24-010073 · form4-04032024_090432.xml · nonDerivative · entry 5

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,518

F2 · shares: Represents RSUs of Certara withheld to satisfy tax withholding obligations in connection with the vesting of RSUs described in footnotes, 1, 4, and 5, exempt under Rule 16b-3.

SEC source: 0001415889-24-010073 · form4-04032024_090432.xml · nonDerivative · entry 4

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each RSU was granted on April 1, 2023, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on April 1, 2024. The remaining two-thirds of the RSUs are scheduled to vest and settle in equal parts on April 1, 2025 and April 1, 2026.

SEC source: 0001415889-24-010073 · form4-04032024_090432.xml · nonDerivative · entry 3

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,356

F2 · shares: Represents RSUs of Certara withheld to satisfy tax withholding obligations in connection with the vesting of RSUs described in footnotes, 1, 4, and 5, exempt under Rule 16b-3.

SEC source: 0001415889-24-010073 · form4-04032024_090432.xml · nonDerivative · entry 2

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each RSU was granted on April 1, 2022, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on March 31, 2023. One-third of the RSUs vested and were settled on April 1, 2024. The remaining one-third of the RSUs are scheduled to vest and settle on April 1, 2025.

SEC source: 0001415889-24-010073 · form4-04032024_090432.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,443

F1 · kind: Each RSU was granted on April 1, 2021, under the Certara, Inc. ("Certara") 2020 Incentive Plan (the "2020 Incentive Plan") and represents the right to receive one share of common stock or the cash equivalent. One-third of the RSUs vested and were settled on April 1, 2022. One-third of the RSUs vested and were settled on March 31, 2023. The remaining one-third of the RSUs vested and were settled on April 1, 2024.

F2 · shares: Represents RSUs of Certara withheld to satisfy tax withholding obligations in connection with the vesting of RSUs described in footnotes, 1, 4, and 5, exempt under Rule 16b-3.

F3 · balance_after: The total reported in Column 5 includes 4,884 RSUs which was previously reported in Table 1 of Form 4

SEC source: 0001415889-24-004633 · form4-02212024_090252.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,975

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2023.

SEC source: 0001415889-23-014040 · form4-10062023_091052.xml · derivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, DRUG DEV SOLUTIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,454

Underlying: Common Stock · 21,454 shares

Expires 2026-10-05

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") was granted on October 5, 2023, under the Certara, Inc. 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent thereof. The RSUs will vest and settle in three equal installments on October 5, 2024, October 5, 2025, and October 5, 2026.

F1 · derivative.exercise_date: Each restricted stock unit ("RSU") was granted on October 5, 2023, under the Certara, Inc. 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent thereof. The RSUs will vest and settle in three equal installments on October 5, 2024, October 5, 2025, and October 5, 2026.

SEC source: 0001415889-23-009326 · form4-06062023_080614.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,975

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2023.

SEC source: 0001415889-23-005808 · form4-04032023_080426.xml · derivative · entry 5

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,556

Underlying: Common Stock · 23,556 shares

Expires 2026-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU was granted on April 1, 2023, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent thereof. The RSUs will vest and settle in three equal installments on April 1, 2024, April 1, 2025, and April 1, 2026.

F5 · derivative.exercise_date: Each RSU was granted on April 1, 2023, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent thereof. The RSUs will vest and settle in three equal installments on April 1, 2024, April 1, 2025, and April 1, 2026.

SEC source: 0001415889-23-005808 · form4-04032023_080426.xml · derivative · entry 4

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,293

Underlying: Common Stock · 8,646 shares

Expires 2025-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU was granted on April 1, 2022, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent thereof. One-third of the RSUs vested and were settled on March 31, 2023. The remaining two-thirds of the RSUs are scheduled to vest and settle in two equal installments on April 1, 2024, and April 1, 2025.

F3 · derivative.exercise_date: Each RSU was granted on April 1, 2022, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent thereof. One-third of the RSUs vested and were settled on March 31, 2023. The remaining two-thirds of the RSUs are scheduled to vest and settle in two equal installments on April 1, 2024, and April 1, 2025.

SEC source: 0001415889-23-005808 · form4-04032023_080426.xml · nonDerivative · entry 3

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,079

F4 · shares: Represents RSUs withheld to satisfy the tax withholding obligations in connection with the vesting and settlement of RSUs, exempt under Rule 16b-3.

F2 · balance_after: The total reported in Column 5 includes 4,884 RSUs which was previously reported in Table 1 of Form 4.

SEC source: 0001415889-23-005808 · form4-04032023_080426.xml · nonDerivative · entry 2

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,973

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: Each RSU was granted on April 1, 2022, under the 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent thereof. One-third of the RSUs vested and were settled on March 31, 2023. The remaining two-thirds of the RSUs are scheduled to vest and settle in two equal installments on April 1, 2024, and April 1, 2025.

F2 · balance_after: The total reported in Column 5 includes 4,884 RSUs which was previously reported in Table 1 of Form 4.

SEC source: 0001415889-23-005808 · form4-04032023_080426.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,327

F1 · shares: Represents restricted stock units ("RSUs") withheld to satisfy the tax withholding obligations in connection with the vesting and settlement of RSUs, exempt under Rule 16b-3. Each RSUs was granted on April 1, 2021, under the Certara, Inc. 2020 Incentive Plan (the "2020 Incentive Plan") and represents a right to receive one share of common stock or the cash equivalent thereof. One-third of the RSUs vested and were settled on April 1, 2022. One-third of the RSUs vested and were on March 31, 2023. The remaining one-third of the RSUs are scheduled to vest and settle on April 1, 2024.

F2 · balance_after: The total reported in Column 5 includes 4,884 RSUs which was previously reported in Table 1 of Form 4.

SEC source: 0001415889-22-011348 · form4-11142022_091110.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,859

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2022.

SEC source: 0001415889-22-011013 · form4-11022022_011117.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,246

F1 · shares: Represents restricted stock units ("RSUs") withheld to satisfy the tax withholding obligations in connection with the vesting and settlement of 3,631 RSUs. The RSUs were granted on November 1, 2021, subject to one-year cliff vesting.

F2 · balance_after: The total reported in column 5 includes 45,404 shares of common stock, 22,074 restricted stock and 9,768 RSUs, each of which was previously reported in Table 1 of Form 4.

SEC source: 0001415889-22-008824 · form4-08182022_020839.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,490

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 11, 2022.

SEC source: 0001415889-22-006381 · form4-06092022_010628.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,490

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2022.

SEC source: 0001415889-22-003827 · form4-04052022_010425.xml · nonDerivative · entry 2

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,490

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021.

F4 · balance_after: The total reported in Column 5 includes 85,091 shares of common stock and 13,399 RSUs, each of which was previously reported in Table 1 of Form 4. Does not include 25,939 newly-awarded RSUs which are reported in Table II.

SEC source: 0001415889-22-003827 · form4-04052022_010425.xml · derivative · entry 3

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,939

Underlying: Common Stock · 25,939 shares

Expires 2025-04-01

F5 · derivative.exercise_price: Each RSU is granted under the Certara, Inc. 2020 Incentive Plan and represents a right to receive one share of common stock or the cash equivalent thereof. The reporting person has reported prior awards of RSUs in Table 1 of Form 4.

F6 · derivative.exercise_date: The RSUs will vest and settle in three equal installments on April 1, 2023, April 1, 2024 and April 1, 2025.

SEC source: 0001415889-22-003827 · form4-04052022_010425.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,842

F1 · shares: Represents restricted stock units ("RSU") withheld to satisfy tax withholding obligations in connection with the vesting and settlement of 4,884 RSUs, previously granted to the reporting person on April 1, 2021. The remaining two-thirds of the RSUs are scheduled to vest and settle in two equal installments on April 1, 2023 and April 1, 2024.

F2 · balance_after: The total reported in Column 5 includes 88,443 shares of common stock and 13,399 RSUs, each of which was previously reported in Table 1 of Form 4. Does not include 25,939 newly-awarded RSUs which are reported in Table II.

SEC source: 0001415889-21-005033 · form4-11012021_011125.xml · nonDerivative · entry 1

SMITH PATRICK F · CIK 0001890360 · PRESIDENT, INTEGRATED DRUG DEV

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,374

F1 · shares: Represents 3,631 restricted stock units ("RSUs") granted to the reporting person that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will cliff vest on November 1, 2022, subject to the continued service of the reporting person through the vesting date.